

## Update on Category III CPT code application

**Sydney:** AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ) wishes to advise that the Company has concluded its presentation to the CPT Editorial Panel Meeting, in relation to its application for a Category III Current Procedural Technology (CPT) code for EchoSolv AS in the US.

The Company is aware of current speculation from media outlets and market participants but wishes to advise it has not received an indication of panel votes at this time. These results will be announced by the American Medical Association (AMA) in the next two to four weeks. Following this, the Company will provide a broader update.

Until such time, Echo IQ will continue to focus on the ongoing deployment of EchoSolv AS with hospital groups, strategic partners and clinics in the US. Concurrently, the Company will continue to progress FDA clearance for EchoSolv HF, new product development, and licencing and partnership opportunities for EchoSolv technology. These activities are advancing well and in line with internal timeframes with additional updates in this regard anticipated shortly.

- ENDS -

**Authorised for release by the Board of Directors of Echo IQ Limited.**

**Investor Enquiries:**

Andrew Grover, Executive Chair  
Andrew.grover@echoiq.ai / investor@echoiq.ai

Henry Jordan, Six Degrees Investor Relations  
Henry.jordan@sdir.com.au / +61 (0) 431 271 538

**ABOUT ECHO IQ**

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology.  
The company is based in Sydney, Australia.